Prostate Cancer Therapeutics Market, by Drug Type,
Distribution Channel, and Geography - Global Trends, and
Forecast to 2025
Prostate cancer is the most common cancer among the geriatric male population. It is a major health
concern, especially in developed countries with a greater proportion of elderly men being affected
by it. According to European Association of Urology, 2016, the incidence is highest in Northern and
Western Europe (> 200 per 100,000 men with age group > 70 years of age), while rates in Eastern
and Southern Europe have showed a continuous increase. Thus, the introduction of innovative drugs
for patients with prostate cancer is required to meet the unmet needs with satisfactory results.
Currently, metastatic castration-resistant prostate cancer (CRPC) is usually treated with
chemotherapy (docetaxel, and cabazitaxel) or secondary hormonal therapeutic agents such as
abiraterone or Triptorelin. Immunotherapy with Sipuleucel-T is prescribed in treating asymptomatic
or minimally metastatic CRPC without visceral metastasis.
Download PDF Brochure Of This Research Report @
https://www.coherentmarketinsights.com/insight/request-pdf/1257
Market Dynamics
The market is gaining significant traction due to continuous investment by research organizations
and universities for the development of therapeutic products for the treatment of such tumors. Novel